|
TABLE 4 | ||||||||||||||||
|
REGENERON PHARMACEUTICALS, INC. COLLABORATION AND OTHER REVENUE (Unaudited) (In thousands) | ||||||||||||||||
|
Three Months EndedJune 30, |
Six Months EndedJune 30, | |||||||||||||||
|
2018 |
2017 |
2018 |
2017 | |||||||||||||
|
Sanofi collaboration revenue: |
||||||||||||||||
|
Reimbursement of Regeneron research and development expenses |
$ |
141,536 |
$ |
205,352 |
$ |
275,754 |
$ |
419,276 |
||||||||
|
Reimbursement of Regeneron commercialization- related expenses |
105,727 |
87,853 |
192,361 |
161,412 |
||||||||||||
|
Regeneron's share of losses in connection with commercialization of antibodies |
(68,797) |
(122,281) |
(143,671) |
(230,683) |
||||||||||||
|
Other |
59,287 |
51,204 |
102,799 |
82,490 |
||||||||||||
|
Total Sanofi collaboration revenue |
237,753 |
222,128 |
427,243 |
432,495 |
||||||||||||
|
Bayer collaboration revenue: |
||||||||||||||||
|
Regeneron's net profit in connection with commercialization of EYLEA outside the United States |
246,302 |
190,883 |
478,370 |
365,759 |
||||||||||||
|
Reimbursement of Regeneron development expenses |
3,867 |
6,720 |
7,864 |
13,069 |
||||||||||||
|
Other |
12,694 |
12,752 |
24,557 |
25,466 |
||||||||||||
|
Total Bayer collaboration revenue |
262,863 |
210,355 |
510,791 |
404,294 |
||||||||||||
|
Total Sanofi and Bayer collaboration revenue |
$ |
500,616 |
$ |
432,483 |
$ |
938,034 |
$ |
836,789 |
||||||||
|
Other revenue: |
||||||||||||||||
|
Reimbursement of Regeneron research and development expenses - Teva |
$ |
34,310 |
$ |
31,481 |
$ |
73,439 |
$ |
53,531 |
||||||||
|
Reimbursement of Regeneron research and development expenses - other |
3,889 |
762 |
6,584 |
3,412 |
||||||||||||
|
Other |
72,825 |
81,257 |
117,159 |
112,997 |
||||||||||||
|
Total other revenue |
$ |
111,024 |
$ |
113,500 |
$ |
197,182 |
$ |
169,940 |
||||||||
